Safety and immunogenicity of aerosolised Ad5-nCoV, intramuscular Ad5-nCoV, or inactivated COVID-19 vaccine CoronaVac given as the second booster following three doses of CoronaVac: a multicentre, open-label, phase 4, randomised trial

BACKGROUND: Aerosolised Ad5-nCoV is the first approved mucosal respiratory COVID-19 vaccine to be used as a booster after the primary immunisation with COVID-19 vaccines. This study aimed to evaluate the safety and immunogenicity of aerosolised Ad5-nCoV, intramuscular Ad5-nCoV, or inactivated COVID-...

Descripción completa

Detalles Bibliográficos
Autores principales: Tang, Rong, Zheng, Hui, Wang, Bu-Sen, Gou, Jin-Bo, Guo, Xi-Ling, Chen, Xiao-Qin, Chen, Yin, Wu, Shi-Po, Zhong, Jin, Pan, Hong-Xing, Zhu, Jia-Hong, Xu, Xiao-Yu, Shi, Feng-Juan, Li, Zhuo-Pei, Liu, Jing-Xian, Zhang, Xiao-Yin, Cui, Lun-Biao, Song, Zhi-Zhou, Hou, Li-Hua, Zhu, Feng-Cai, Li, Jing-Xin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Ltd. 2023
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9991083/
https://www.ncbi.nlm.nih.gov/pubmed/36898400
http://dx.doi.org/10.1016/S2213-2600(23)00049-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9991083/
https://www.ncbi.nlm.nih.gov/pubmed/36898400
http://dx.doi.org/10.1016/S2213-2600(23)00049-8

Ejemplares similares